{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:50:42Z","timestamp":1789041042076,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jcyt.2023.05.011","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T13:41:10Z","timestamp":1687268470000},"page":"930-938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R\/R B-ALL) treatment in children and young adults"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8807-1257","authenticated-orcid":false,"given":"Aur\u00e9lio Matos","family":"Andrade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit\u00f3ria Rodrigues","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Claudia Morais Godoy","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-0523","authenticated-orcid":false,"given":"Juliana Lott","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2023.05.011_bib0001","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon, France: World Health Organization; 2008."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0002","series-title":"Cancer Facts & Figures 2022","year":"2022"},{"issue":"16","key":"10.1016\/j.jcyt.2023.05.011_bib0003","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0004","series-title":"SEER Cancer Statistics Review (CSR) 1975-2013","author":"Howlader","year":"2015"},{"issue":"6","key":"10.1016\/j.jcyt.2023.05.011_bib0005","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0006","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.12778","article-title":"SWOG S0910: a phase 2 trial of clofarabine\/cytarabine\/epratuzumab for relapsed\/refractory acute lymphocytic leukaemia","volume":"165","author":"Advani","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0007","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0008","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jcyt.2023.05.011_bib0009","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2010.09.020","article-title":"ALL-REZ BFM Study Group. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group","volume":"47","author":"von Stackelberg","year":"2011","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.jcyt.2023.05.011_bib0010","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.clinthera.2021.02.006","article-title":"Advanced therapies and regulatory framework in different areas of the globe: past, present, and future","volume":"43","author":"Pimenta","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0011","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrd3052","article-title":"Challenges with advanced therapy medicinal products and how to meet them","volume":"9","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0012","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/bcp.14275","article-title":"A systematic review of economic evaluations of advanced therapy medicinal products","volume":"87","author":"Lloyd-Williams","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jcyt.2023.05.011_bib0013","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O'Leary","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0014","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl JMed"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0015","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/jama.2017.15218","article-title":"FDA approval of tisagenlecleucel: promise and complexities of a $475000 cancer drug","volume":"318","author":"Bach","year":"2017","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.jcyt.2023.05.011_bib0016","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMp1807382","article-title":"National coverage analysis of CAR-T therapies: policy, evidence, and payment","volume":"379","author":"Bach","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.jcyt.2023.05.011_bib0017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2017.156","article-title":"immunotherapy: tisagenlecleucel: the first approved CAR-T-cell therapy: implications for payers and policy makers","volume":"15","author":"Prasad","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0018","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.19.01558","article-title":"Valuing chimeric antigen receptor T-cell therapy: current evidence, uncertainties, and payment implications","volume":"38","author":"Whittington","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jcyt.2023.05.011_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"18","author":"Page","year":"2021","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.jcyt.2023.05.011_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health."},{"issue":"7","key":"10.1016\/j.jcyt.2023.05.011_bib0021","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jclinepi.2013.02.004","article-title":"The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses","volume":"66","author":"Mustafa","year":"2013","journal-title":"J Clin Epidemiol."},{"issue":"32","key":"10.1016\/j.jcyt.2023.05.011_bib0022","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jcyt.2023.05.011_bib0023","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","article-title":"Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia","volume":"172","author":"Whittington","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.jcyt.2023.05.011_bib0024","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ejh.13427","article-title":"Cost-effectiveness of anti-CD19 chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia. A societal view","volume":"105","author":"Thielen","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/CEOR.S241880","article-title":"Cost-effectiveness analysis of tisagenlecleucel in the treatment of relapsed or refractory B-cell acute lymphoblastic leukaemia in children and young adults in Spain","volume":"12","author":"Ribera Santasusana","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"issue":"7","key":"10.1016\/j.jcyt.2023.05.011_bib0026","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djy193","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"111","author":"Sarkar","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.jcyt.2023.05.011_bib0027","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jtct.2020.12.023","article-title":"Cost-effectiveness analysis of tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia in Japan","volume":"27","author":"Wakase","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0028","series-title":"Aspectos de Qualidade cr\u00edticos para Farmacovigil\u00e2ncia de Medicamentos de Terapia G\u00e9nica - C\u00e9lulas Geneticamente Modificadas","author":"Louren\u00e7o","year":"2019"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0029","unstructured":"European Commission. Good Manufacturing Practice for Advanced Therapy Medicinal Products. 4 (1): 1-90. 2017. <https:\/\/www.ema.europa.eu\/en\/news\/new-guidelines-good-manufacturing-practices-advanced-therapies>; 2017 [accessed 06.16.2023]."},{"issue":"1","key":"10.1016\/j.jcyt.2023.05.011_bib0030","first-page":"1","article-title":"Biologics vs. small molecules: drug costs and patient access","volume":"9","author":"Makurvet","year":"2021","journal-title":"Med Drug Discov"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0031","unstructured":"Albuquerque FC. Intercambialidade de biossimilares - uma proposta de pol\u00edtica p\u00fablica para o SUS. (Tese de doutorado) - Universidade Cat\u00f3lica de Bras\u00edlia 2017."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0032","series-title":"Pharmaceutical production\u08e7an engineering guide","first-page":"457","author":"Bennett","year":"2003"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0033","series-title":"Farmacot\u00e9cnica, Formas Farmac\u00eauticas & Sistema de Libera\u00e7\u00e3o de F\u00e1rmacos. 6\u00aa Edi\u00e7\u00e3o","first-page":"568","author":"Ansel","year":"2000"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0034","unstructured":"Food and Drug Administration (FDA). Package Insert-KYMRIAH. <https:\/\/www.fda.gov\/media\/107296\/download>; 2003 [accessed 06.16.2023]."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0035","unstructured":"European Medicines Agency (EMA). Kymriah, INN-tisagenlecleucel. <https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kymriah-epar-product-information_en.pdf>; 2003 [accessed 06.16.2023]."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0036","unstructured":"Food and Drug Administration (FDA). Clolar (clofarabine) label. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021673s024lbl.pdf>; 2003 [accessed 06.16.2023]."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0037","unstructured":"European Medicines Agency (EMA). Evoltra, INN-clofarabina. <https:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150918132770\/anx_132770_pt.pdf>; 2003 [accessed 06.16.2023]."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0038","unstructured":"Food and Drug Administration (FDA). BLINCYTO\u00ae (blinatumomab) for injection. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125557s013lbl.pdf>; 2003 [accessed 06.16.2023]."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0039","unstructured":"European Medicines Agency (EMA). Blincyto, INN-blinatumomab. <https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blincyto-epar-product-information_en.pdf>; 2003 [accessed 06.16.2023]."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0040","unstructured":"Food and Drug Administration (FDA). Fludara\u00ae (fludarabine phosphate). <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020038s032lbl.pdf>; 2003 [accessed 06.16.2023]."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0041","unstructured":"Food and Drug Administration (FDA). DEPOCYT (cytarabine liposome injection) Label. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021041s031lbl.pdf>; 2003 [accessed 06.16.2023]."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0042","unstructured":"Food and Drug Administration (FDA). Idamycin PFS\u00ae idarubicin hydrochloride injection. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/050734s027lbl.pdf>; 2003 [accessed 13.03.03]."},{"issue":"9","key":"10.1016\/j.jcyt.2023.05.011_bib0043","doi-asserted-by":"crossref","first-page":"e29123","DOI":"10.1002\/pbc.29123","article-title":"Tisagenlecleucel for treatment of children and young adults with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"68","author":"Si Lim","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.jcyt.2023.05.011_bib0044","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2019.5909","article-title":"Cost-effectiveness of tisagenlecleucel vs standard care in high-risk relapsed pediatric acute lymphoblastic leukemia in Canada","volume":"6","author":"Furzer","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.jcyt.2023.05.011_bib0045","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjmed.2018.05.020","article-title":"Death or debt? National estimates of financial toxicity in persons with newly-diagnosed cancer","volume":"131","author":"Gilligan","year":"2018","journal-title":"Am J Med."},{"issue":"suppl 1","key":"10.1016\/j.jcyt.2023.05.011_bib0046","first-page":"609","article-title":"Cost-effectiveness analysis of CTL019 for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia in the United States","volume":"130","author":"Hao","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jcyt.2023.05.011_bib0047","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/jnci\/djn175","article-title":"Evaluation of trends in the cost of initial cancer treatment","volume":"100","author":"Warren","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.jcyt.2023.05.011_bib0048","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12874-019-0823-8","article-title":"Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"19","author":"Cope","year":"2019","journal-title":"BMC Med Res Methodol"},{"issue":"36","key":"10.1016\/j.jcyt.2023.05.011_bib0049","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jcyt.2023.05.011_bib0050","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0051","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/j.clml.2017.07.030","article-title":"Global Registry Trial of Efficacy and Safety of CTL019 in Pediatric Patients and Young Adults with Relapsing\/Refractory (R\/R) Acute Lymphoblastic Leukemia (ALL): update to interim analysis","volume":"17","author":"Buechner","year":"2017","journal-title":"Clinical Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0052","unstructured":"ClinicalTrials.gov. Study of efficacy and safety of CTL019 in pediatric ALL patients (ELIANA), <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02435849>, [accessed 26.11.2021]."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0053","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood-2019-128288","article-title":"Prophylactic itacitinib (INCB039110) for the prevention of cytokine release syndrome induced by chimeric antigen receptor T-cells (CAR-T-cells) therapy","volume":"134","author":"Huarte","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0054","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1016\/j.bbmt.2019.12.436","article-title":"Trial in progress: a phase 2, single-arm, open-label study of itacitinib (ITA) for the prevention of chimeric antigen receptor (CAR) T-cell\u2013induced cytokine release syndrome (CRS)","volume":"26","author":"Park","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"10.1016\/j.jcyt.2023.05.011_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"Suppl 4","key":"10.1016\/j.jcyt.2023.05.011_bib0056","article-title":"How I treat adverse effects of CAR-T cell therapy","volume":"4","author":"Y\u00e1\u00f1ez","year":"2020","journal-title":"ESMO Open."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0057","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","author":"Morris","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2023.05.011_bib0058","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jcyt.2023.05.011_bib0059","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/0272989X16639900","article-title":"Extrapolating survival from randomized trials using external data: a review of methods","volume":"37","author":"Jackson","year":"2017","journal-title":"Med Decis Mak"},{"issue":"26","key":"10.1016\/j.jcyt.2023.05.011_bib0060","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.jcyt.2023.05.011_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.547653","article-title":"Two decades of global progress in authorized advanced therapy medicinal products: an emerging revolution in therapeutic strategies","volume":"8","author":"Ramezankhani","year":"2020","journal-title":"Front Cell Dev Biol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492300957X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492300957X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T05:14:20Z","timestamp":1726895660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532492300957X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S146532492300957X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.05.011","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R\/R B-ALL) treatment in children and young adults","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}